IL33 and familial dilated cardiomyopathy: Our results support these previous findings, as we observed that CORM‐2 treatment alleviated heart injury and cardiomyocyte pyroptosis by downregulating the IL‐33/ST2L axis in DCM, whereas iCORM‐2 demonstrated no effects.